Drug Profile
SR 80258A
Latest Information Update: 01 Sep 1998
Price :
$50
*
At a glance
- Originator Sanofi-Synthelabo
- Class Anticoagulants; Antithrombotics; Low molecular weight heparins
- Mechanism of Action Thrombin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Ischaemic heart disorders; Thrombosis
Most Recent Events
- 01 Sep 1998 No-Development-Reported for Ischaemic heart disorders in USA (Unknown route)
- 01 Sep 1998 No-Development-Reported for Thrombosis in USA (Unknown route)
- 07 Dec 1995 Preclinical development for Ischaemic heart disorders in USA (Unknown route)